CTLA4 and neoplasm: Similarly, expression of the granzyme B T-cell activity marker and immune checkpoint proteins programmed death (PD)-1 and cytotoxic T-lymphocyte antigen (CTLA)-4 did not significantly decrease with either treatment based on immunohistochemistry (Supplementary Fig. 9a) or on protein levels in tumor lysates (Supplementary Fig. 9b).